Boston Scientific Corporation vs Commvault Systems Inc — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Commvault Systems Inc trades at $139.62 (market cap $5.78B). The key difference: Boston Scientific Corporation is far larger — about 12.4× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | CVLT | |
|---|---|---|
Market Cap | $71.46B | $5.78B |
Sector | Health | Technology |
52-Week High | $108.14 | $195.41 |
52-Week Low | $42.63 | $75.18 |
Enterprise Value | $83.55B | $5.77B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Commvault Systems (CVLT) trades at $135.27, up 1.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with an 81.09% gross margin and 32.77% ROE, though valuation multiples like a P/E of 89.38 are elevated. Recent news highlights growth in SaaS revenue and new security integrations, such as the Threat Scan partnership with Google, driving positive analyst sentiment.
The outlook remains positive with a consensus price target of $172.40, implying 27% upside, supported by subscription growth and cash flow improvements. Risks include high valuation sensitivity, competitive pressures in data security, and fiduciary duty investigations noted in recent legal alerts, which could impact investor confidence near-term.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →